In a nutshell This study examined how treatment with ibrutinib (Imbruvica), rituximab (Rituxan), and bendamustine (Treanda) impacts quality of life in chronic lymphocytic leukemia (CLL) patients. Factors such as fatigue, physical functioning, and well-being were all improved among those patients with the lowest scores before treatment. Some background...
Read MoreCurrent disease status-Recurrent leukemia Posts on Medivizor
What effect do different stem cell types have in transplantation for patients with acute leukemia?
In a nutshell This study aimed to evaluate the effect of stem cell source on haploidentical transplantation with post-transplantation cyclophosphamide (a chemotherapy) in patients with acute leukemia. This study concluded that the use of peripheral blood stem cells increases the risk of side effects for these patients. Some background Patients...
Read MoreAn overview of the dose management of dasatinib
In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...
Read MoreLooking for participants with relapse of childhood B-lymphoblastic leukemia to receive blinatumomab
In a nutshell This phase 3 trial aims to determine the effect of blinatumomab compared to standard chemotherapy in treating patients with B-cell acute lymphoblastic leukemia after a relapse (return of cancer after a period of improvement). The outcome to be measured is the survival rate over 10 years. The details Acute lymphoblastic leukemia...
Read MoreCombined haploidentical-cord stem cell transplantation in lymphoma and CLL – what are the outcomes?
In a nutshell This study analyzed the outcomes of lymphoma and chronic lymphoblastic leukemia (CLL) patients who received haplo-cord stem cell transplantation. The study concluded that this method gives higher rates of engraftment and lower rates of graft-versus-host disease (GVHD) compared to haploidentical transplant. Some background High-risk...
Read MoreSalvage chemotherapy options for relapsed/refractory acute myeloid leukemia
In a nutshell This study aimed to compare two salvage chemotherapy regimens for relapsed/refractory acute myeloid leukemia. This study concluded that there were no significant differences between the two regimens apart from cost. Some background Salvage chemotherapy is used to treat cancers that do not respond to other treatments. Relapsed...
Read MoreGood response rates to venetoclax in patients previously treated with ibrutinib
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with ibrutinib (Imbruvica). Researchers reported good disease control and a low rate of side effects venetoclax after ibrutinib. Some background Targeted therapy is the standard treatment of CLL. This includes the Bruton...
Read MoreA new treatment combination for patients with relapsed Philadelphia chromosome positive leukemia
In a nutshell This study aimed to investigate the combination of blinatumomab (Blincyto) and a tyrosine kinase inhibitor in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia. This study concluded that this combination was safe and effective for this group of patients. Some background Philadelphia...
Read MoreCAR-T cell therapy and infection risk
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read MoreA review of venetoclax for previously treated CLL
In a nutshell This study reviewed evidence on venetoclax (Venclexta) for previously treated chronic lymphocytic leukemia (CLL). Some background Targeted therapy is the standard treatment of CLL. This includes the BCL2 inhibitor therapy venetoclax. BCL2 inhibitor therapy blocks a protein called BCL2 involved in leukemia cell growth. Venetoclax has...
Read MoreGender affects outcomes of rituximab-based treatment
In a nutshell This study examined the effect of gender on treatment outcomes with chemo-immunotherapy for chronic lymphocytic leukemia (CLL). Researchers reported better survival and disease progression outcomes for female patients receiving rituximab-based (Rituxan) therapy. Some background Men are more likely to develop CLL than women....
Read MoreInside the First FDA-Approved CAR-T Cell Therapy
Video Information: The first CAR T-cell therapy to receive FDA approval, CTL019 (Kymriah) was recently approved for children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. Expert Dr. Michael Deinginger joins Patient Power Founder Andrew Schorr to explain CAR T-cell...
Read More
